estradiol acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
estrogens	4497	4245-41-4

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

estradiol acetate

Molecular weight: 314.43
Formula: C20H26O3
CLOGP: 3.80
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 46.53
ALOGS: -5.24
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
March 20, 2003	FDA	WARNER IRELAND

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	59.16	52.48	36	149	1044729	62444108

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA CS	M0447348	Estradiol Congeners
FDA MoA	N0000000100	Estrogen Receptor Agonists
MeSH PA	D004967	Estrogens
MeSH PA	D006728	Hormones
FDA EPC	N0000175825	Estrogen
CHEBI has role	CHEBI:50114	estrogens
CHEBI has role	CHEBI:62872	quinoline oxidase inhibitors
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite
CHEBI has role	CHEBI:83056	Daphnia magna metabolites
CHEBI has role	CHEBI:176497	geroprotectors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Atrophic vaginitis	indication	52441000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.45MG	FEMTRACE	APIL	N021633	Aug. 20, 2004	DISCN	TABLET	ORAL	7572779	Oct. 2, 2025	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
0.9MG	FEMTRACE	APIL	N021633	Aug. 20, 2004	DISCN	TABLET	ORAL	7572779	Oct. 2, 2025	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
1.8MG	FEMTRACE	APIL	N021633	Aug. 20, 2004	DISCN	TABLET	ORAL	7572779	Oct. 2, 2025	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Estrogen receptor	Nuclear hormone receptor	P03372	ESR1_HUMAN	AGONIST				CHEMBL	CHEMBL

External reference:

ID	Source
D04061	KEGG_DRUG
4025444	VUID
N0000175999	NUI
4017609	VANDF
4021205	VANDF
4025444	VANDF
CHEBI:16469	CHEBI
EST	PDB_CHEM_ID
CHEMBL1200430	ChEMBL_ID
CHEMBL1611800	ChEMBL_ID
DB13952	DRUGBANK_ID
5R97F5H93P	UNII
DB00783	DRUGBANK_ID
405416	RXNORM
17173	MMSL
4684	MMSL
6157	MMSL
73244	MMSL
8602	MMSL
d00537	MMSL
001265	NDDF
009983	NDDF
126172005	SNOMEDCT_US
12839006	SNOMEDCT_US
414140005	SNOMEDCT_US
C1330622	UMLSCUI
C0014912	UMLSCUI
9818306	PUBCHEM_CID
406	INN_ID
5757	PUBCHEM_CID
D004958	MESH_DESCRIPTOR_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Femring	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6030	RING	0.10 mg	VAGINAL	NDA	15 sections
Femring	HUMAN PRESCRIPTION DRUG LABEL	1	72495-201	RING	0.05 mg	VAGINAL	NDA	31 sections
Femring	HUMAN PRESCRIPTION DRUG LABEL	1	72495-201	RING	0.05 mg	VAGINAL	NDA	31 sections
Femring	HUMAN PRESCRIPTION DRUG LABEL	1	72495-202	RING	0.10 mg	VAGINAL	NDA	31 sections
Femring	HUMAN PRESCRIPTION DRUG LABEL	1	72495-202	RING	0.10 mg	VAGINAL	NDA	31 sections